Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAVOUR: Atuliflapon in CAD
NCT03317002Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of atuliflapon in coronary artery disease (CAD), sponsored by AstraZeneca. Started Oct 2017; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03317002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317002.